Enanta reports Phase I data for NASH/PBC candidate

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) reported data from a Phase Ia/Ib trial in 98 healthy volunteers and 48 patients with presumed non-alcoholic fatty liver disease (NAFLD) showing that oral EDP-305 was generally well tolerated with no serious adverse events reported. The trial evaluated single doses of 1, 5, 10, 20, 40 and 80 mg EDP-305 in volunteers, and doses of 0.5, 1, 2.5, 5, 10 and 20 mg EDP-305 for 14 days in volunteers and patients.

The double-blind, placebo-controlled, U.S. trial's primary endpoint is safety, with a secondary endpoint of pharmacokinetics...